Prostatic Neoplasms, Castration-Resistant Active Not Recruiting Phase 3 Trials for Atezolizumab (DB11595)

DBCOND0001230 (Prostatic Neoplasms, Castration-Resistant)Active Not Recruiting3 IdentifierTitlePurposeDrugs
NCT03016312A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane RegimenTreatment